Impact Biomedical (IBO) Accumulated Expenses (2022 - 2026)
Impact Biomedical's (IBO) quarterly Accumulated Expenses came in at $210000.0 in Q1 2026, down 3.23% YoY from $217000.0 in Q1 2025, and up 8.25% on a QoQ basis from $194000.0 in Q4 2025.
Impact Biomedical (IBO) Accumulated Expenses (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Accumulated Expenses data on file, last reported at $210000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 3.23% year-over-year to $210000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $210000.0 (down 3.23% YoY) and the FY2025 annual result came in at $194000.0, changed 0.0% from the prior year.
- Accumulated Expenses rose to $210000.0 in Q1 2026, from $194000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $336000.0 in Q3 2025 to a low of $6000.0 in Q3 2023.
- A 5-year average of $160500.0 and a median of $194000.0 in 2024 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 1600.0% in 2024, down 15.65% in 2024.
- Tracing IBO's Accumulated Expenses over 5 years: stood at $63000.0 in 2022, then surged by 265.08% to $230000.0 in 2023, then declined by 15.65% to $194000.0 in 2024, then changed by 0.0% to $194000.0 in 2025, then advanced by 8.25% to $210000.0 in 2026.
- The last three Accumulated Expenses figures came in at $210000.0 (Q1 2026), $194000.0 (Q4 2025), and $336000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248,000.00 |
| Mar 31, 2026 | 210,000.00 |
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 336,000.00 |
| Jun 30, 2025 | 266,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Dec 31, 2024 | 194,000.00 |
| Sep 30, 2024 | 102,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 47,000.00 |
| Dec 31, 2023 | 230,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Dec 31, 2022 | 63,000.00 |